GO:0045814 negative regulation of gene expression, epigenetic: Silencing Pathways, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045814 describes an epigenetic process that silences gene expression at specific genomic regions through chromatin remodeling, histone modification, or DNA methylation.
• Key molecular players include DNA methyltransferases (DNMT1, DNMT3A, DNMT3B), histone deacetylases (HDAC1-11), histone methyltransferases (EZH2, SETDB1, SUV39H1), and reader proteins such as TRIM28.
• Epigenetic silencing is essential for normal development, X-chromosome inactivation, genomic imprinting, and maintenance of cell identity.
• Dysregulation of this process contributes to cancer, inflammatory bowel disease-associated colorectal cancer, cholangiocarcinoma, and autoimmune conditions such as lupus.
• The SETDB1-TRIM28 complex exemplifies how epigenetic silencing suppresses antitumor immunity, making it a target for cancer immunotherapy.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of epigenetic silencing components in disease contexts.
Description
Epigenetic silencing is a fundamental biological process that ensures genes are expressed at the right time, in the right cell type, and at the right level. GO:0045814, negative regulation of gene expression, epigenetic, captures the mechanisms by which cells heritably repress transcription without altering the underlying DNA sequence. This process is critical for development, differentiation, and maintenance of cellular identity, and its disruption is increasingly recognized as a driver of human disease. Understanding GO:0045814 is therefore essential for researchers in cancer biology, immunology, developmental biology, and regenerative medicine. The term encompasses diverse molecular strategies, including DNA methylation, histone deacetylation, histone methylation, and higher-order chromatin remodeling. These mechanisms converge on the same outcome: stable, locus-specific gene silencing. Recent studies have revealed that epigenetic silencing is not merely a static repressive state but a dynamic, regulated process that can be reversed or reprogrammed. For example, C/EBPβ-dependent epigenetic memory in hematopoietic stem cells demonstrates how silencing programs can be inherited through cell divisions to induce trained immunity. Similarly, interferon signaling can subvert an AHR-JUN axis to promote CXCL13+ T cells in lupus, highlighting the interplay between epigenetic regulation and immune function. In cancer, whole-genome and epigenomic landscapes of cholangiocarcinoma have uncovered distinct epigenetic subtypes that correlate with etiology and clinical outcome. These findings underscore the importance of GO:0045814 as a framework for understanding both normal physiology and disease pathogenesis.
negative regulation of gene expression, epigenetic At A Glance
| GO ID | GO:0045814 |
|---|---|
| GO term | negative regulation of gene expression, epigenetic |
| Ontology | biological_process |
| Synonym | gene silencing; downregulation of gene expression, epigenetic; inhibition of gene expression, epigenetic |
| Major function | Heritable silencing of specific genomic regions via chromatin remodeling, histone modification, or DNA methylation |
| Key molecular players | DNMT1, DNMT3A, DNMT3B, HDAC1-11, EZH2, SETDB1, TRIM28, SUV39H1, HP1 proteins |
| Cellular context | Nucleus; chromatin; CpG islands; pericentromeric heterochromatin |
| Biological outcomes | X-chromosome inactivation, genomic imprinting, cell fate maintenance, suppression of repetitive elements |
| Disease relevance | Cancer, inflammatory bowel disease-associated colorectal cancer, cholangiocarcinoma, lupus, trained immunity |
What Is GO:0045814?
GO:0045814, negative regulation of gene expression, epigenetic, is defined as an epigenetic process that silences gene expression at specific genomic regions through chromatin remodeling, either by modifying higher order chromatin fiber structure, nucleosomal histones, or cytosine DNA methylation. In simpler terms, it is the set of molecular mechanisms that switch genes off in a heritable manner without changing the DNA sequence. This includes the addition of methyl groups to DNA, chemical modifications of histone tails, and the repositioning or compaction of nucleosomes. These modifications recruit reader proteins that further reinforce the silent state, creating a self-propagating repressive chromatin environment.
Why Is negative regulation of gene expression, epigenetic Important in Cell Biology?
GO:0045814 is important because epigenetic silencing is a central mechanism for controlling gene expression programs during development and disease. It ensures that genes are repressed in a stable and heritable manner, which is essential for maintaining cell identity and preventing inappropriate gene activation. Disruption of this process can lead to widespread transcriptional dysregulation, contributing to cancer, autoimmune diseases, and inflammatory conditions. Moreover, epigenetic silencing is reversible, making it an attractive target for therapeutic intervention, as exemplified by HDAC inhibitors in cancer therapy.
• Maintains cell identity by stably repressing lineage-inappropriate genes.
• Mediates X-chromosome inactivation and genomic imprinting in mammals.
• Suppresses transposable elements and repetitive sequences to preserve genome stability.
• Dysregulated in cancer, including cholangiocarcinoma and colorectal cancer, where epigenetic subtypes influence prognosis.
• Plays a role in immune cell function and autoimmunity, such as CXCL13+ T cell promotion in lupus.
• Contributes to trained immunity in hematopoietic stem cells via C/EBPβ-dependent epigenetic memory.
• Targeted by HDAC inhibitors and other epigenetic drugs in cancer therapy.
• Regulates developmental processes such as endochondral bone formation through Tbx18 silencing.
• Influences hypoxia-inducible gene expression after HIF activation.
• The SETDB1-TRIM28 complex suppresses antitumor immunity, linking epigenetic silencing to immune evasion.
What Happens During negative regulation of gene expression, epigenetic?
DNA Methylation and Maintenance of Silencing
In simple terms: Cells add chemical tags to DNA to keep certain genes switched off.
DNA methylation is a primary epigenetic mechanism for long-term gene silencing. DNMT3A and DNMT3B establish de novo methylation at CpG dinucleotides, while DNMT1 maintains methylation patterns during DNA replication. Methylated CpG islands recruit methyl-CpG-binding proteins that further recruit histone deacetylases and histone methyltransferases, reinforcing the silent state. In cholangiocarcinoma, distinct DNA methylation profiles define etiologically distinct subtypes, demonstrating the clinical relevance of this process.
Histone Deacetylation and Chromatin Compaction
In simple terms: Proteins remove acetyl groups from histones, causing DNA to wrap more tightly and genes to turn off.
Histone deacetylases (HDACs) remove acetyl groups from lysine residues on histone tails, leading to chromatin compaction and transcriptional repression. HDAC inhibitors have shown promise in cancer therapy by reversing this silencing and reactivating tumor suppressor genes. The balance between histone acetyltransferases (HATs) and HDACs is critical for maintaining appropriate gene expression programs.
Histone Methylation and Reader Protein Recruitment
In simple terms: Cells add methyl marks to histones that act as docking sites for proteins that keep genes off.
Histone methyltransferases such as EZH2 (H3K27me3), SUV39H1 (H3K9me3), and SETDB1 (H3K9me3) deposit repressive marks on histone tails. These marks are recognized by reader proteins like HP1 and TRIM28, which recruit additional silencing factors. The SETDB1-TRIM28 complex is a paradigm of this mechanism, suppressing antitumor immunity by silencing immune-related genes.
Higher-Order Chromatin Remodeling and Nuclear Organization
In simple terms: Large regions of DNA are folded into tight structures that keep many genes off at once.
Beyond individual nucleosomes, epigenetic silencing involves higher-order chromatin remodeling that compacts large genomic regions into heterochromatin. This includes the formation of facultative heterochromatin marked by H3K27me3 and constitutive heterochromatin marked by H3K9me3. Nuclear organization, such as tethering to the nuclear lamina or polycomb bodies, further reinforces silencing. In hematopoietic stem cells, C/EBPβ-dependent epigenetic memory induces trained immunity, demonstrating how higher-order chromatin changes can encode long-term functional states.
Dynamic Regulation and Reversibility
In simple terms: Gene silencing can be reversed by enzymes that remove chemical marks.
Epigenetic silencing is not permanent; it can be reversed by enzymes such as TET dioxygenases (DNA demethylation) and histone demethylases (e.g., KDM4, KDM6). This reversibility is exploited therapeutically, as HDAC inhibitors and DNA methyltransferase inhibitors can reactivate silenced genes. In lupus, interferon signaling subverts an AHR-JUN axis to promote CXCL13+ T cells, illustrating how external signals can remodel the epigenetic landscape.
Key Genes Involved in GO:0045814 negative regulation of gene expression, epigenetic
The following genes encode core components and regulators of epigenetic silencing under GO:0045814.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DNMT1 | Maintenance DNA methyltransferase | Essential for propagating methylation patterns during replication |
| DNMT3A | De novo DNA methyltransferase | Establishes new methylation marks during development and cancer |
| DNMT3B | De novo DNA methyltransferase | Implicated in cancer and developmental disorders |
| HDAC1 | Histone deacetylase | Removes acetyl groups to repress transcription; target of HDAC inhibitors |
| HDAC2 | Histone deacetylase | Functions in chromatin compaction and gene silencing |
| HDAC3 | Histone deacetylase | Involved in nuclear receptor-mediated repression |
| EZH2 | H3K27 methyltransferase | Component of Polycomb repressive complex 2; silences developmental genes |
| SETDB1 | H3K9 methyltransferase | Suppresses antitumor immunity in complex with TRIM28 |
| TRIM28 | Scaffold protein | Recruits SETDB1 and HP1 to silence genes |
| SUV39H1 | H3K9 methyltransferase | Establishes constitutive heterochromatin |
| HP1 | Heterochromatin protein | Binds H3K9me3 and propagates silencing |
| C/EBPβ | Transcription factor | Mediates epigenetic memory in hematopoietic stem cells |
| AHR | Aryl hydrocarbon receptor | Modulates epigenetic states in T cells |
| JUN | Transcription factor | Interferon-regulated axis in lupus T cells |
| Tbx18 | Transcription factor | Epigenetically regulated during endochondral bone formation |
| HIF | Hypoxia-inducible factor | Regulates hypoxia-inducible gene expression |
| TET1 | DNA demethylase | Reverses DNA methylation to activate genes |
How Is negative regulation of gene expression, epigenetic Regulated?
Epigenetic silencing is regulated at multiple levels. External signals such as interferon can modulate the AHR-JUN axis to alter T cell epigenetic states. Hypoxia-inducible factors (HIFs) regulate gene expression after activation, indirectly influencing epigenetic landscapes. In hematopoietic stem cells, C/EBPβ-dependent epigenetic memory induces trained immunity, showing that transcription factors can instruct heritable silencing programs. Additionally, the SETDB1-TRIM28 complex is subject to regulation by immune signaling, and its suppression of antitumor immunity can be reversed by targeted inhibition.
negative regulation of gene expression, epigenetic and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SETDB1 | Cancer immunotherapy resistance | Knockout in tumor cells followed by immune cell co-culture |
| DNMT3A | Cholangiocarcinoma | Point mutation knock-in in cholangiocyte organoids |
| HDAC1 | Colorectal cancer | Overexpression in colorectal cancer cell lines |
| C/EBPβ | Trained immunity | Knockout in hematopoietic stem cells |
| AHR | Lupus | Knockout in T cells followed by interferon stimulation |
Cancer and Epigenetic Silencing
Dysregulation of GO:0045814 is a hallmark of many cancers. In cholangiocarcinoma, whole-genome and epigenomic analyses have revealed distinct epigenetic subtypes associated with different etiologies and clinical outcomes. Inflammatory bowel disease-associated colorectal cancer exhibits genetic and epigenetic characteristics that drive tumorigenesis. HDAC inhibitors are being developed to reverse aberrant silencing and reactivate tumor suppressor genes. The SETDB1-TRIM28 complex suppresses antitumor immunity, and its inhibition can enhance immune responses against tumors.
Autoimmunity and Lupus
Epigenetic silencing contributes to autoimmune diseases such as lupus. Interferon signaling subverts an AHR-JUN axis to promote CXCL13+ T cells, which are implicated in lupus pathogenesis. This highlights how environmental triggers can alter epigenetic programs and drive autoimmunity.
Trained Immunity and Hematopoietic Stem Cells
C/EBPβ-dependent epigenetic memory in hematopoietic stem cells induces trained immunity, a form of innate immune memory. This demonstrates that epigenetic silencing mechanisms can be co-opted to encode long-term functional states in stem cells, with implications for vaccine design and immunotherapy.
Developmental and Bone Disorders
Epigenetic regulation of Tbx18 gene expression during endochondral bone formation is critical for skeletal development. Disruption of such silencing mechanisms can lead to developmental abnormalities. Additionally, hypoxia-inducible gene expression after HIF activation is regulated epigenetically, with implications for ischemic diseases.
From negative regulation of gene expression, epigenetic-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SETDB1 reactivate immune genes? | SETDB1 knockout in cancer cell lines |
| Does a specific DNMT3A mutation alter methylation? | Point mutation knock-in in iPSCs |
| Can C/EBPβ epigenetic memory be inherited? | C/EBPβ knockout in hematopoietic stem cells |
| Does HDAC1 overexpression drive colorectal cancer? | HDAC1 overexpression in colon organoids |
| How does AHR-JUN axis affect T cell silencing? | AHR knockout in primary T cells |
| Can TET1 reactivate silenced genes? | TET1 overexpression in cancer cells |
How to Study the negative regulation of gene expression, epigenetic Process
| Method | What It Measures | Typical Application |
|---|---|---|
| WGBS | DNA methylation at single-base resolution | Identifying methylated regions in cancer |
| ChIP-seq | Protein-DNA binding and histone modifications | Mapping SETDB1/TRIM28 binding sites |
| RNA-seq | Gene expression levels | Detecting reactivated genes after HDAC inhibition |
| ATAC-seq | Chromatin accessibility | Assessing chromatin compaction after silencing |
| dCas9-DNMT3A | Locus-specific DNA methylation | Targeted gene silencing |
| Mass spectrometry | Histone post-translational modifications | Quantifying acetylation and methylation changes |
| CRISPR screen | Genome-wide fitness and silencing factors | Identifying regulators of epigenetic silencing |
Genome-Wide Methylation Profiling
Whole-genome bisulfite sequencing (WGBS) and reduced representation bisulfite sequencing (RRBS) measure DNA methylation at single-base resolution. These methods are used to identify differentially methylated regions in diseases such as cholangiocarcinoma and colorectal cancer.
Chromatin Immunoprecipitation Sequencing (ChIP-seq)
ChIP-seq with antibodies against histone modifications (e.g., H3K9me3, H3K27me3) or silencing proteins (e.g., SETDB1, TRIM28) maps their genomic binding sites. This reveals how epigenetic silencing complexes are targeted to specific loci.
Transcriptomic Analysis (RNA-seq)
RNA-seq quantifies gene expression changes upon perturbation of epigenetic silencing factors. It is used to identify genes reactivated by HDAC inhibitors or SETDB1 knockout.
CRISPR-Based Epigenetic Editing
Fusion of catalytically dead Cas9 (dCas9) to epigenetic modifiers (e.g., DNMT3A, KRAB) enables locus-specific silencing or activation. This approach allows causal testing of epigenetic marks at individual genes.
How CRISPR Can Be Used to Study GO:0045814 negative regulation of gene expression, epigenetic
Knockout
CRISPR knockout of epigenetic silencing genes (e.g., SETDB1, DNMT1, HDAC1) is used to assess their role in gene repression and disease phenotypes. For example, SETDB1 knockout in cancer cells reactivates immune genes and enhances antitumor immunity.
Point Mutation
Point mutations in catalytic domains of DNMT3A or HDACs can be introduced to dissect enzymatic activity from scaffolding functions. This is particularly useful for understanding how specific mutations in epigenetic regulators contribute to cancer.
Knock-in
Knock-in of tagged versions of silencing proteins (e.g., SETDB1-FLAG, TRIM28-HA) enables chromatin immunoprecipitation and proteomic studies to identify interacting partners and genomic targets.
Overexpression
Overexpression of epigenetic silencing factors such as HDAC1 or EZH2 in cell lines or organoids models their oncogenic roles and allows testing of targeted inhibitors.
How EDITGENE Supports negative regulation of gene expression, epigenetic Research
Researchers studying negative regulation of gene expression, epigenetic-related genes often need to determine whether a candidate gene is causally involved in silencing, chromatin remodeling, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from knockout and point mutation to knock-in, overexpression, and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of gene expression, epigenetic research.
Frequently Asked Questions About negative regulation of gene expression, epigenetic
What is GO:0045814?
GO:0045814 is the Gene Ontology term for negative regulation of gene expression, epigenetic, defined as an epigenetic process that silences gene expression at specific genomic regions through chromatin remodeling, histone modification, or DNA methylation.
What genes are involved in negative regulation of gene expression, epigenetic?
Key genes include DNMT1, DNMT3A, DNMT3B, HDAC1-11, EZH2, SETDB1, TRIM28, SUV39H1, and HP1.
How does epigenetic silencing work?
It involves DNA methylation, histone deacetylation, histone methylation, and higher-order chromatin remodeling that together repress transcription.
What diseases are associated with epigenetic silencing?
Cancer, inflammatory bowel disease-associated colorectal cancer, cholangiocarcinoma, lupus, and developmental disorders.
What is the role of SETDB1 in epigenetic silencing?
SETDB1 is a histone methyltransferase that, in complex with TRIM28, deposits H3K9me3 to silence genes and suppress antitumor immunity.
How can I study epigenetic silencing in the lab?
Methods include WGBS, ChIP-seq, RNA-seq, ATAC-seq, and CRISPR-based epigenetic editing.
What are HDAC inhibitors?
HDAC inhibitors are drugs that block histone deacetylases, reversing epigenetic silencing and reactivating genes, and are used in cancer therapy.
What is the link between epigenetic silencing and trained immunity?
C/EBPβ-dependent epigenetic memory in hematopoietic stem cells induces trained immunity, demonstrating heritable silencing programs.
How does interferon affect epigenetic silencing in lupus?
Interferon subverts an AHR-JUN axis to promote CXCL13+ T cells, altering epigenetic states in lupus.
What CRISPR models are available for epigenetic silencing research?
EDITGENE offers knockout, point mutation, knock-in, overexpression, and library screening services for epigenetic silencing genes.
Conclusion
GO:0045814, negative regulation of gene expression, epigenetic, is a fundamental biological process that controls gene silencing through DNA methylation, histone modifications, and chromatin remodeling. Its dysregulation is implicated in cancer, autoimmunity, and developmental disorders, making it a critical area of research. Advances in CRISPR-based models and epigenomic profiling are accelerating our understanding of these mechanisms and enabling the development of targeted therapies. EDITGENE provides comprehensive services to support researchers in dissecting the causal roles of epigenetic silencing genes in health and disease.
References
- 1. Ramaiah MJ et al.. 2021. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.. Life Sci 277:119504 PMID: 33872660
- 2. Jusakul A et al.. 2017. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.. Cancer Discov 7(10):1116-1135 PMID: 28667006
- 3. de Laval B et al.. 2020. C/EBPβ-Dependent Epigenetic Memory Induces Trained Immunity in Hematopoietic Stem Cells.. Cell Stem Cell 26(5):657-674.e8 PMID: 32169166
- 4. Law C et al.. 2024. Interferon subverts an AHR-JUN axis to promote CXCL13(+) T cells in lupus.. Nature 631(8022):857-866 PMID: 38987586
- 5. Rajamäki K et al.. 2021. Genetic and Epigenetic Characteristics of Inflammatory Bowel Disease-Associated Colorectal Cancer.. Gastroenterology 161(2):592-607 PMID: 33930428
- 6. Haraguchi R et al.. 2015. Epigenetic regulation of Tbx18 gene expression during endochondral bone formation.. Cell Tissue Res 359(2):503-512 PMID: 25380565
- 7. Suzuki N et al.. 2017. Regulation of hypoxia-inducible gene expression after HIF activation.. Exp Cell Res 356(2):182-186 PMID: 28286304
- 8. Lin J et al.. 2021. The SETDB1-TRIM28 Complex Suppresses Antitumor Immunity.. Cancer Immunol Res 9(12):1413-1424 PMID: 34848497
